https://plustherapeutics.com/recurrent-glioblastoma/
Recurrent glioblastoma (GBM) is a fatal, treatment-resistant, malignant brain tumor that causes numerous neurological complications.
plus therapeuticsrecurrentglioblastomapstv
https://stockhouse.com/companies/quote?symbol=pstv
Get today's stock prices, news and investor discussion about Plus Therapeutics Inc (NDAQ:PSTV). Research PSTV stock prices, stock quotes, stock trends and...
plus therapeuticsstock pricetoday newsincndaq
https://www.biospace.com/elevar-therapeutics-announces-camrelizumab-plus-rivoceranib-significantly-prolonged-overall-survival-and-progression-free-survival-versus-sorafenib-in-patients-with-unresectable-hepatocellular-carcinoma-during-phase-3-trial
Elevar Therapeutics, Inc. announced top-line results from the Phase 3 study of its drug candidate rivoceranib combined with camrelizumab versus sorafenib as a...
therapeuticsannouncescamrelizumabplusrivoceranib
https://www.benzinga.com/trading-ideas/movers/25/03/44190619/plus-therapeutics-continues-rally-on-friday-heres-why
Plus Therapeutics stock rises after peer-reviewed publication of Phase 1 glioma data and FDA Orphan Drug Designation for lung cancer treatment.
plus therapeuticscontinuesrallyfriday